Resistance to iV-Benzyladriamycin-14-valerate in Mouse J774.2 Cells

P-Glycoprotein Expression without Reduced 7V-Benzyladriamycin-14-valerate Accumulation

Leonard Lothstein, Trevor W. Sweatman, Michael E. Dockter, Mervyn Israel

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

/V-Benzyladriamycin-14-valerate (AD 198) is a highly lipophilic analogue of Adriamycin with novel cytotoxic mechanisms, greater in vivo antitumor activity, and the ability to circumvent multidrug resistance due to P-glycoprotein-mediated drug efflux or decreased topoisomerase II activity. To identify the mechanism(s) which may confer AD 198 resistance, J774.2 mouse macrophage-like cells were selected for growth in cytotoxic levels of AD 198 (AD 198”). AD 198R cells exhibited over-expression of the mdrlb (P-glycoprotein) gene, cross-resistance to Adriamycin and vinblastine, and potentiation of drug cytotoxicity by verapamil. However, net intracellular accumulation of AD 198 in AD 198R cells was unchanged compared to parental cells, while Adriamycin and vinblastine accumulations were reduced 40% and 95%, respectively. AD 198 was localized in the perinuclear region of the cytoplasm in both parental and AD 198R cells, with additional vesicular compartmentalization in AD 198” cells. Verapamil-induced reversal of AD 198 resistance coincided with some drug redistribution from cytoplasmic vesicles, but without redistribution of AD 198 into the nucleus. These results suggest that AD 198 resistance was not conferred through a P-glycoprotein-mediated reduction in intracellular drug accumulation but through other cytoplasmic mechanisms, including, but not limited to, drug compartmentalization.

Original languageEnglish (US)
Pages (from-to)3409-3417
Number of pages9
JournalCancer Research
Volume52
Issue number12
StatePublished - Jan 1 1992

Fingerprint

Valerates
P-Glycoprotein
Doxorubicin
Vinblastine
Verapamil
Pharmaceutical Preparations
Drug Synergism
N-benzyladriamycin-14-valerate
Cytoplasmic Vesicles
Type II DNA Topoisomerase
Multiple Drug Resistance
Cytoplasm
Macrophages

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Resistance to iV-Benzyladriamycin-14-valerate in Mouse J774.2 Cells : P-Glycoprotein Expression without Reduced 7V-Benzyladriamycin-14-valerate Accumulation. / Lothstein, Leonard; Sweatman, Trevor W.; Dockter, Michael E.; Israel, Mervyn.

In: Cancer Research, Vol. 52, No. 12, 01.01.1992, p. 3409-3417.

Research output: Contribution to journalArticle

@article{22d00744832e4c09b96a7f08a0557b7b,
title = "Resistance to iV-Benzyladriamycin-14-valerate in Mouse J774.2 Cells: P-Glycoprotein Expression without Reduced 7V-Benzyladriamycin-14-valerate Accumulation",
abstract = "/V-Benzyladriamycin-14-valerate (AD 198) is a highly lipophilic analogue of Adriamycin with novel cytotoxic mechanisms, greater in vivo antitumor activity, and the ability to circumvent multidrug resistance due to P-glycoprotein-mediated drug efflux or decreased topoisomerase II activity. To identify the mechanism(s) which may confer AD 198 resistance, J774.2 mouse macrophage-like cells were selected for growth in cytotoxic levels of AD 198 (AD 198”). AD 198R cells exhibited over-expression of the mdrlb (P-glycoprotein) gene, cross-resistance to Adriamycin and vinblastine, and potentiation of drug cytotoxicity by verapamil. However, net intracellular accumulation of AD 198 in AD 198R cells was unchanged compared to parental cells, while Adriamycin and vinblastine accumulations were reduced 40{\%} and 95{\%}, respectively. AD 198 was localized in the perinuclear region of the cytoplasm in both parental and AD 198R cells, with additional vesicular compartmentalization in AD 198” cells. Verapamil-induced reversal of AD 198 resistance coincided with some drug redistribution from cytoplasmic vesicles, but without redistribution of AD 198 into the nucleus. These results suggest that AD 198 resistance was not conferred through a P-glycoprotein-mediated reduction in intracellular drug accumulation but through other cytoplasmic mechanisms, including, but not limited to, drug compartmentalization.",
author = "Leonard Lothstein and Sweatman, {Trevor W.} and Dockter, {Michael E.} and Mervyn Israel",
year = "1992",
month = "1",
day = "1",
language = "English (US)",
volume = "52",
pages = "3409--3417",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Resistance to iV-Benzyladriamycin-14-valerate in Mouse J774.2 Cells

T2 - P-Glycoprotein Expression without Reduced 7V-Benzyladriamycin-14-valerate Accumulation

AU - Lothstein, Leonard

AU - Sweatman, Trevor W.

AU - Dockter, Michael E.

AU - Israel, Mervyn

PY - 1992/1/1

Y1 - 1992/1/1

N2 - /V-Benzyladriamycin-14-valerate (AD 198) is a highly lipophilic analogue of Adriamycin with novel cytotoxic mechanisms, greater in vivo antitumor activity, and the ability to circumvent multidrug resistance due to P-glycoprotein-mediated drug efflux or decreased topoisomerase II activity. To identify the mechanism(s) which may confer AD 198 resistance, J774.2 mouse macrophage-like cells were selected for growth in cytotoxic levels of AD 198 (AD 198”). AD 198R cells exhibited over-expression of the mdrlb (P-glycoprotein) gene, cross-resistance to Adriamycin and vinblastine, and potentiation of drug cytotoxicity by verapamil. However, net intracellular accumulation of AD 198 in AD 198R cells was unchanged compared to parental cells, while Adriamycin and vinblastine accumulations were reduced 40% and 95%, respectively. AD 198 was localized in the perinuclear region of the cytoplasm in both parental and AD 198R cells, with additional vesicular compartmentalization in AD 198” cells. Verapamil-induced reversal of AD 198 resistance coincided with some drug redistribution from cytoplasmic vesicles, but without redistribution of AD 198 into the nucleus. These results suggest that AD 198 resistance was not conferred through a P-glycoprotein-mediated reduction in intracellular drug accumulation but through other cytoplasmic mechanisms, including, but not limited to, drug compartmentalization.

AB - /V-Benzyladriamycin-14-valerate (AD 198) is a highly lipophilic analogue of Adriamycin with novel cytotoxic mechanisms, greater in vivo antitumor activity, and the ability to circumvent multidrug resistance due to P-glycoprotein-mediated drug efflux or decreased topoisomerase II activity. To identify the mechanism(s) which may confer AD 198 resistance, J774.2 mouse macrophage-like cells were selected for growth in cytotoxic levels of AD 198 (AD 198”). AD 198R cells exhibited over-expression of the mdrlb (P-glycoprotein) gene, cross-resistance to Adriamycin and vinblastine, and potentiation of drug cytotoxicity by verapamil. However, net intracellular accumulation of AD 198 in AD 198R cells was unchanged compared to parental cells, while Adriamycin and vinblastine accumulations were reduced 40% and 95%, respectively. AD 198 was localized in the perinuclear region of the cytoplasm in both parental and AD 198R cells, with additional vesicular compartmentalization in AD 198” cells. Verapamil-induced reversal of AD 198 resistance coincided with some drug redistribution from cytoplasmic vesicles, but without redistribution of AD 198 into the nucleus. These results suggest that AD 198 resistance was not conferred through a P-glycoprotein-mediated reduction in intracellular drug accumulation but through other cytoplasmic mechanisms, including, but not limited to, drug compartmentalization.

UR - http://www.scopus.com/inward/record.url?scp=0026718971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026718971&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 3409

EP - 3417

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -